2023

Effect of High-Dose Direct Anticoagulant Drugs and DOAC-Remove™ on Lupus Anticoagulant Detection by a Hexagonal Phase Phospholipid Assay

2022

Validation of a New Kit for the Determination of Factor IX Activity

Performance of FVIII Deficient Plasma with VWF in the Activity Measurement of FVIII Replacement Products in Plasma Samples Using an OSC Assay

Performance of a Chromogenic Factor IX Activity Assay in the Recovery of Factor IX Replacement Therapies

Hypercoagulability in COVID-19: Is there an Antiphospholipid Syndrome?

2021

Impact of Inactive FVIII Antigen in FVIII Deficient Plasma on the Measurement of FVIII Inhibitors

Comparison of a Chromogenic vs APTT-based FVIII Activity Assay in the Recovery of a Pegylated FVIII Replacement Therapy in Plasma Samples

Validation of a New Kit for the Quantitative Determination of Chromogenic FIX Activity

Laboratory Validation of CRYOcheck™ Chromogenic Factor VIII Across Multiple Coagulation Analyzers

2020

Comparison of Hexagonal Phase Phospholipid Neutralization Assays for Lupus Anticoagulant Detection

Performance of CRYOcheck™ Chromogenic Factor VIII in the Recovery of Factor VIII Replacement Therapies

CRYOcheck™ Chromogenic Factor VIII: A New Kit for the Determination of FVIII:C Activity

Laboratory Validation of a Novel Hexagonal Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Detection

Effects of Anticoagulants and Common Interfering Substances on Four Commercially Available dRVVT Assays

2019

Effects of Common Interferents in Hexagonal Phase Phospholipid Neutralization Testing

2018 and Earlier

A Standardized Kit for a Chromogenic Modified Nijmegen-Bethesda Assay: Repeatability, Reproducibility, and Analytical Sensitivity

Emicizumab Impact on Factor VIII Inhibitor Determination in Plasma Samples from Persons with Hemophilia A Using a New Kit for Modified Nijmegen-Bethesda Assay

Agreement Between a Chromogenic Modified Nijmegen-Bethesda Assay and a Qualitative ELISA test in Detection of Factor VIII Inhibitors in Plasma from Persons with Hemophilia A

Performance of a New Kit for a Modified Nijmegen-Bethesda Assay: Comparison of a Chromogenic Versus a Clot-based Factor VIII Inhibitor Assay in Plasma from Persons with Hemophilia A

Assessment of clotting activity of recombinant FIX Fc fusion protein in European HTCs
(Poster available to healthcare professionals only; login required)

Recombinant Factor IX Fc Fusion Protein (rFIXFc) Clotting Activity Assessment in International Hemophilia Treatment Centers

Assessment of clotting activity of recombinant factor IX Fc fusion protein (rFIXFc) in plasma samples at haemophilia treatment centres in Australia and New Zealand

Assessment of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Clotting Activity in Plasma Samples at Canadian Hemophilia Treatment Centres

PF4-R, a Novel Heparin Neutralizing Reagent Suitable for Automated Coagulometers: Comparison with Heparinase in Routine Coagulation Tests

I have hemophilia and I am okay! Infographic

Pipe S, Sadeghi-Khomami A, Konkle BA, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. 2023;1-10.

Sommer JM, Sadeghi-Khomami A, Barnowski C, Wikén M, Willemze AJ. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples. Int J Lab Hematol. 2020;42:350–358.